TT20X

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameTT20X
Drug Alias NameTT20X
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionCD276 antigen modulatorsTumor necrosis factor receptor superfamily member 8 modulatorsEpstein-Barr virus inhibitors
TargetsCD276 antigenTumor necrosis factor receptor superfamily member 8Epstein-Barr virus
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTessa Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTessa Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A